Quarter Period Consolidated Statement Of Comprehensive Income

Daito Pharmaceutical Co., Ltd. - Filing #7289262

Concept 2024-06-01 to
2024-11-30
2023-06-01 to
2023-11-30
Quarter period consolidated statement of comprehensive income
Statement of comprehensive income
Profit (loss)
718,000,000 JPY
1,494,000,000 JPY
Other comprehensive income
Valuation difference on available-for-sale securities
-480,000,000 JPY
76,000,000 JPY
Foreign currency translation adjustment
-5,000,000 JPY
61,000,000 JPY
Remeasurements of defined benefit plans, net of tax
-16,000,000 JPY
-50,000,000 JPY
Other comprehensive income
-502,000,000 JPY
87,000,000 JPY
Comprehensive income
215,000,000 JPY
1,581,000,000 JPY
Comprehensive income attributable to
Comprehensive income attributable to owners of parent
406,000,000 JPY
1,622,000,000 JPY
Comprehensive income attributable to non-controlling interests
-190,000,000 JPY
-40,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.